A database of FDA approved therapeutic peptides and proteins
ID1001 | ThPPIDTh1001 | NameLepirudin | Peptide SequenceLVYTDCTESGQNLCLCEGSN Full view | Length65 | Functional ClassificationIa | DiseaseHematological,Metabolic | BrandRefludan | CompanyBerlex Labs | Physical AppearanceSterile, white, freeze-dried powder | Route of AdministartionIntravenous infusion | CategoryAntithrombins and Fibrinolytic Agents | TargetProthrombin |
ID1025 | ThPPIDTh1004 | NameDenileukin diftitox | Peptide SequenceMGADDVVDSSKSFVMENFSS Full view | Length255 | Functional ClassificationIIb | DiseaseCancer | BrandOntak | CompanySeragen Inc | Physical AppearanceSterile, white, preservative-free, lyophilized powder. | Route of AdministartionIntravenous(IV) administration | CategoryAntineoplastic Agents | TargetInterleukin-2 receptor subunit alpha,Interleukin-2 receptor subunit beta,Cytokine receptor common subunit gamma |
ID1028 | ThPPIDTh1005 | NameEtanercept | Peptide SequenceLPAQVAFTPYAPEPGSTCRL Full view | Length255 | Functional ClassificationIIa | DiseaseImmunological | BrandEnbrel | CompanyImmunex Corp | Physical AppearanceLyophilized powder. | Route of AdministartionSubcutaneous injection | CategoryImmunosuppressive Agents | TargetTumor necrosis factor,Tumor necrosis factor receptor superfamily member 1B,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor II-c,Lymphotoxin-alpha,Low affinity immunoglobulin gamma Fc region re |
ID1033 | ThPPIDTh1006 | NameBivalirudin | Peptide SequenceFPRPGGGGNGDFEEIPEEYL Full view | Length20 | Functional ClassificationIa | DiseaseHematological,Metabolic | BrandAngiox | CompanyThe Medicines Company UK Ltd | Physical AppearancePowder for concentrate for solution | Route of AdministartionInjection | CategoryAntithrombins | TargetProthrombin |
ID1055 | ThPPIDTh1009 | NameAlteplase | Peptide SequenceSYQVICRDEKTQMIYQQHQS Full view | Length255 | Functional ClassificationIb | DiseaseHematological,Metabolic | BrandActivase | CompanyGenentech Inc | Physical AppearanceSterile, white to off-white, lyophilized powder | Route of AdministartionIntravenous | CategoryThrombolytic Agents | TargetPlasminogen,Fibrinogen alpha chain,Urokinase plasminogen activator surface receptor,Plasminogen activator inhibitor 1 |
ID1067 | ThPPIDTh1012 | NameReteplase | Peptide SequenceSYQGNSDCYFGNGSAYRGTH Full view | Length255 | Functional ClassificationIb | DiseaseHematological,Metabolic | BrandRetavase | CompanyCentocor | Physical AppearanceSterile, white, lyophilized powder | Route of AdministartionIntravenous Injection | CategoryFibrinolytic Agents, Thrombolytic agents | TargetPlasminogen,Fibrinogen alpha chain,Urokinase plasminogen activator surface receptor,Plasminogen activator inhibitor 1 |
ID1077 | ThPPIDTh1013 | NameEpoetin alfa | Peptide SequenceAPPRLICDSRVLERYLLEAK Full view | Length166 | Functional ClassificationIb | DiseaseHematological | BrandNanokine | CompanyNanogen Pharmaceutical biotechnology, Vietnam) | Physical AppearanceSterile, white, lyophilized powder. The reconstituted preparation with 1 ml solvent (containing 0.9% benzyl alcohol) results in a clear, colorless solution. | Route of AdministartionInjection | CategoryAnti-anemic Agents, Hematinics | TargetErythropoietin receptor |
ID1121 | ThPPIDTh1017 | NameSargramostim | Peptide SequenceAPARSPSPSTQPWEHVNAIQ Full view | Length127 | Functional ClassificationIb | DiseaseImmunological | BrandLeukine | CompanyBerlex Laboratories Inc | Physical AppearanceSterile, preserved (1.1% benzyl alcohol), injectable solution (500 mcg/mL) and also as sterile, white, preservative free lyophilized powder (250 mcg) that requires reconstitution with 1 mL sterile water for Injection | Route of AdministartionSubcutaneous Injection (SC) or Intravenous infusion (IV) | CategoryImmunosuppressive Agents | TargetGranulocyte-macrophage colony-stimulating factor receptor subunit alpha,Interleukin-3 receptor subunit alpha,Cytokine receptor common subunit beta,Syndecan-2,Bone marrow proteoglycan |
ID1129 | ThPPIDTh1018 | NameSecretin | Peptide SequenceHSDGTFTSELSRLRDSARLQ Full view | Length27 | Functional ClassificationIV | DiseaseHormonal disorders | BrandSecreFlo | CompanyRepligen Corp | Physical AppearanceLyophilized white powder | Route of AdministartionIntravenous infusion | CategoryDiagnostic Agents | TargetSecretin receptor |
ID1135 | ThPPIDTh1019 | NamePeginterferon alfa-2b | Peptide SequenceCDLPQTHSLGSRRTLMLLAQ Full view | Length165 | Functional ClassificationIb | DiseaseImmunological | BrandPEG-Intron | CompanySchering Corp | Physical AppearancePowder | Route of AdministartionSubcutaneous injection | CategoryImmunosuppressive Agents | TargetInterferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
ID1136 | ThPPIDTh1019 | NamePeginterferon alfa-2b | Peptide SequenceCDLPQTHSLGSRRTLMLLAQ Full view | Length165 | Functional ClassificationIb | DiseaseImmunological | BrandUnitron PEG | CompanyN.A. | Physical AppearanceLyophilized powder | Route of AdministartionSubcutaneous injection | CategoryImmunosuppressive Agents | TargetInterferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
ID1142 | ThPPIDTh1020 | NameAsparaginase | Peptide SequenceQMSLQQELRYIEALSAIVET Full view | Length255 | Functional ClassificationIc | DiseaseCancer | BrandElspar | CompanyMerck & Co. Inc | Physical AppearanceLyophilized plug or powder | Route of AdministartionIntravenous or Intramuscular. Intravenous method dose has higher risk of allergic reaction, so often a test dose is given first. | CategoryAntineoplastic Agents | TargetL-asparagine |
ID1145 | ThPPIDTh1021 | NameThyrotropin Alfa | Peptide SequenceAlpha chain:APDVQDC< Full view | Length204 | Functional ClassificationIV | DiseaseCancer | BrandThyrogen | CompanyGenzyme Inc | Physical AppearanceLyophilized powder | Route of AdministartionIntramuscular preferably the buttocks | CategoryDiagnostic Agents | TargetThyrotropin receptor |
ID1148 | ThPPIDTh1022 | NameAntihemophilic Factor | Peptide SequenceATRRYYLGAVELSWDYMQSD Full view | Length255 | Functional ClassificationIa | DiseaseHematological,Metabolic | BrandAdvate | CompanyN.A. | Physical AppearancePowder form | Route of AdministartionIntravenous Injection | CategoryCoagulants and Thrombotic agents | TargetCoagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
ID1149 | ThPPIDTh1022 | NameAntihemophilic Factor | Peptide SequenceATRRYYLGAVELSWDYMQSD Full view | Length255 | Functional ClassificationIa | DiseaseHematological,Metabolic | BrandAlphanate | CompanyN.A. | Physical AppearanceLyophilized powder | Route of AdministartionIntravenous Injection | CategoryCoagulants and Thrombotic agents | TargetCoagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
ID1150 | ThPPIDTh1022 | NameAntihemophilic Factor | Peptide SequenceATRRYYLGAVELSWDYMQSD Full view | Length255 | Functional ClassificationIa | DiseaseHematological,Metabolic | BrandBioclate | CompanyBaxter Healthcare Corporation, Hyland Division and Genetics Institute, Inc. | Physical AppearanceSterile, nonpyrogenic, off-white to faint yellow, lyophilized powder | Route of AdministartionIntravenous infusion | CategoryCoagulants and Thrombotic agents | TargetCoagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
ID1153 | ThPPIDTh1022 | NameAntihemophilic Factor | Peptide SequenceATRRYYLGAVELSWDYMQSD Full view | Length255 | Functional ClassificationIa | DiseaseHematological,Metabolic | BrandHyate:C | CompanyN.A. | Physical AppearancePowder | Route of AdministartionIntravenous Injection | CategoryCoagulants and Thrombotic agents | TargetCoagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
ID1154 | ThPPIDTh1022 | NameAntihemophilic Factor | Peptide SequenceATRRYYLGAVELSWDYMQSD Full view | Length255 | Functional ClassificationIa | DiseaseHematological,Metabolic | BrandKoate-HP | CompanyN.A. | Physical AppearancePowder | Route of AdministartionIntravenous Injection | CategoryCoagulants and Thrombotic agents | TargetCoagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
ID1155 | ThPPIDTh1022 | NameAntihemophilic Factor | Peptide SequenceATRRYYLGAVELSWDYMQSD Full view | Length255 | Functional ClassificationIa | DiseaseHematological,Metabolic | BrandKogenate FS | CompanyN.A. | Physical AppearancePowder | Route of AdministartionIntravenous Injection | CategoryCoagulants and Thrombotic agents | TargetCoagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
ID1156 | ThPPIDTh1022 | NameAntihemophilic Factor | Peptide SequenceATRRYYLGAVELSWDYMQSD Full view | Length255 | Functional ClassificationIa | DiseaseHematological,Metabolic | BrandMonarc-M | CompanyN.A. | Physical AppearancePowder | Route of AdministartionIntravenous Injection | CategoryCoagulants and Thrombotic agents | TargetCoagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
ID1157 | ThPPIDTh1022 | NameAntihemophilic Factor | Peptide SequenceATRRYYLGAVELSWDYMQSD Full view | Length255 | Functional ClassificationIa | DiseaseHematological,Metabolic | BrandMonoclate-P | CompanyN.A. | Physical AppearanceLyophilized powder for solution | Route of AdministartionIntravenous Injection | CategoryCoagulants and Thrombotic agents | TargetCoagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
ID1158 | ThPPIDTh1022 | NameAntihemophilic Factor | Peptide SequenceATRRYYLGAVELSWDYMQSD Full view | Length255 | Functional ClassificationIa | DiseaseHematological,Metabolic | BrandReFacto | CompanyN.A. | Physical AppearanceLyophilized powder | Route of AdministartionIntravenous Injection | CategoryCoagulants and Thrombotic agents | TargetCoagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
ID1159 | ThPPIDTh1022 | NameAntihemophilic Factor | Peptide SequenceATRRYYLGAVELSWDYMQSD Full view | Length255 | Functional ClassificationIa | DiseaseHematological,Metabolic | BrandXyntha | CompanyN.A. | Physical AppearanceSterile, nonpyrogenic, preservative-free, freeze-dried powder | Route of AdministartionIntravenous Injection | CategoryCoagulants and Thrombotic agents | TargetCoagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
ID1201 | ThPPIDTh1026 | NameAnistreplase | Peptide SequenceSYQVICRDEKTQMIYQQHQS Full view | Length255 | Functional ClassificationIc | DiseaseHematological,Metabolic | BrandEminase | CompanyWulfing Pharma GmbH | Physical AppearanceDry powder | Route of AdministartionIntravenous infusion | CategoryThrombolytic Agents, Fibrinolytic agents | TargetPlasminogen,Fibrinogen alpha chain,Urokinase plasminogen activator surface receptor,Plasminogen activator inhibitor 1 |
ID1210 | ThPPIDTh1028 | NameTenecteplase | Peptide SequenceSYQVICRDEKTQMIYQQHQS Full view | Length255 | Functional ClassificationIb | DiseaseHematological,Metabolic | BrandTNKase | CompanyGenentech Inc | Physical AppearanceSterile, white to off-white, lyophilized powder | Route of AdministartionIntravenous Injection | CategoryThrombolytic Agents, Fibrinolytic agents | TargetPlasminogen,Fibrinogen alpha chain,Urokinase plasminogen activator surface receptor,Plasminogen activator inhibitor 1,Plasminogen activator inhibitor 2,Tetranectin,Keratin, type II cytoskeletal 8,Annexin A2,Calreticulin,Calnexin,Prolow-density lipoprotein |
ID1215 | ThPPIDTh1029 | NameMenotropins | Peptide SequenceAlpha-Chain(LH):APD< Full view | Length222 | Functional ClassificationIb | DiseaseHormonal disorders | BrandMenopur | CompanyN.A. | Physical AppearanceSterile, lyophilized powder which is reconstitution with sterile 0.9% Sodium Chloride Injection. | Route of AdministartionSubcutaneous Injection | CategoryFertility Agents | TargetFollicle-stimulating hormone receptor,Lutropin-choriogonadotropic hormone receptor |
ID1234 | ThPPIDTh1032 | NameCoagulation factor VIIa | Peptide SequenceANAFLEELRPGSLERECKEE Full view | Length255 | Functional ClassificationIb | DiseaseHematological,Metabolic | BrandNovoSeven | CompanyNovo Nordisk | Physical AppearanceSterile, white lyophilized powder | Route of AdministartionInjection | CategoryThrombotic Agents, Coagulants | TargetCoagulation factor X,Serine protease hepsin,Tissue factor pathway inhibitor,Vitamin K-dependent gamma-carboxylase,Coagulation factor VII,Tissue factor |
ID1242 | ThPPIDTh1033 | NameOprelvekin | Peptide SequenceGPPPGPPRVSPDPRAELDST Full view | Length177 | Functional ClassificationIb | DiseaseCancer/Haemetological | BrandNeumega | CompanyGenetics Institute Inc | Physical AppearanceSterile, lyophilized powder | Route of AdministartionSubcutaneous injection | CategoryCoagulants and Thrombotic Agents, Anti-neoplastic agents | TargetInterleukin-11 receptor subunit alpha |
ID1246 | ThPPIDTh1034 | NamePalifermin | Peptide SequenceSYDYMEGGDIRVRRLFCRTQ Full view | Length140 | Functional ClassificationIb | DiseaseCancer | BrandKepivance | CompanyAmgen Inc | Physical AppearanceSterile, lyophilized powder | Route of AdministartionIntravenous infusion | CategoryAnti-Mucositis Agents | TargetFibroblast growth factor receptor 2,Neuropilin-1,Fibroblast growth factor receptor 1,Fibroblast growth factor receptor 4,Fibroblast growth factor receptor 3,Basement membrane-specific heparan sulfate proteoglycan core protein |
ID1252 | ThPPIDTh1035 | NameGlucagon recombinant | Peptide SequenceHSQGTFTSDYSKYLDSRRAQ Full view | Length29 | Functional ClassificationIV | DiseaseHormonal/Metabolic/genetic | BrandGlucaGen | CompanyNovo Nordisk | Physical AppearanceSterile, lyophilized white powder | Route of AdministartionSubcutaneous, Intramuscular, or Intravenous infusion | CategoryHypoglycemic Agents | TargetGlucagon receptor,Glucagon-like peptide 2 receptor,Glucagon-like peptide 1 receptor |
ID1253 | ThPPIDTh1035 | NameGlucagon recombinant | Peptide SequenceHSQGTFTSDYSKYLDSRRAQ Full view | Length29 | Functional ClassificationIV | DiseaseHormonal/Metabolic/genetic | BrandGlucagon | CompanyEli Lilly | Physical AppearancePowder | Route of AdministartionSubcutaneously or Intramuscularly Injection | CategoryHypoglycemic Agents | TargetGlucagon receptor,Glucagon-like peptide 2 receptor,Glucagon-like peptide 1 receptor |
ID1290 | ThPPIDTh1042 | NameCollagenase | Peptide SequenceMKRKCLSKRLMLAITMATIF Full view | Length255 | Functional ClassificationIc | DiseaseHematological | BrandXiaflex | CompanyAuxilium | Physical AppearanceSterile lyophilized powder (white cake) | Route of AdministartionIntralesional Injection | CategoryN.A. | TargetCollagen alpha-1(I) chain,Collagen alpha-1(II) chain,Collagen alpha-1(III) chain,Collagen alpha-2(I) chain |
ID1305 | ThPPIDTh1043 | NameRasburicase | Peptide SequenceSAVKAARYGKDNVRVYKVHK Full view | Length255 | Functional ClassificationIc | DiseaseMetabolic/Genetic | BrandElitek | CompanySanofi-Synthelabo Inc | Physical AppearanceSterile, white to off-white, lyophilized powder | Route of AdministartionIntravenous administration | CategoryAntihyperuricemic Agents, Gout suppressants | TargetUric acid |
ID1306 | ThPPIDTh1043 | NameRasburicase | Peptide SequenceSAVKAARYGKDNVRVYKVHK Full view | Length255 | Functional ClassificationIc | DiseaseMetabolic/Genetic | BrandFasturtec | CompanyN.A. | Physical AppearancePowder and solvent that are made upto make solution. | Route of AdministartionIntravenous administartion | CategoryAntihyperuricemic Agents, Gout suppressants | TargetUric acid |
ID1331 | ThPPIDTh1047 | NameAlpha-1-proteinase inhibitor | Peptide SequenceEDPQGDAAQKTDTSHHDQDH Full view | Length255 | Functional ClassificationIIa | DiseaseMetabolic/Geneti/Respiratory | BrandAralast | CompanyBaxter | Physical AppearanceLyophilized powder | Route of AdministartionIntravenous infusion | CategorySerine Proteinase Inhibitors, Enzyme replacement agents, trypsin inhibitors | TargetNeutrophil elastase |
ID1332 | ThPPIDTh1047 | NameAlpha-1-proteinase inhibitor | Peptide SequenceEDPQGDAAQKTDTSHHDQDH Full view | Length255 | Functional ClassificationIIa | DiseaseMetabolic/Geneti/Respiratory | BrandProlastin | CompanyTalecris Biotherapeutics C formerly Bayer | Physical AppearanceLyophilized powder | Route of AdministartionIntravenous infusion | CategorySerine Proteinase Inhibitors, Enzyme replacement agents, trypsin inhibitors | TargetNeutrophil elastase |
ID1341 | ThPPIDTh1049 | NameInterferon beta-1a | Peptide SequenceMSYNLLGFLQRSSNFQCQKL Full view | Length166 | Functional ClassificationIb | DiseaseCancer/Infectious/Immunological | BrandAvonex | CompanyBiogen Inc | Physical AppearanceLyophilized powder vial, Sterile liquid as single used prefilled syringe and also available as single use prefilled autoinjector. | Route of AdministartionIntramuscular Injection | CategoryImmunosuppressive Agents, Antineoplastic, Antiviral, Immunologic factors | TargetInterferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
ID1342 | ThPPIDTh1049 | NameInterferon beta-1a | Peptide SequenceMSYNLLGFLQRSSNFQCQKL Full view | Length166 | Functional ClassificationIb | DiseaseCancer/Infectious/Immunological | BrandBetaferon | CompanyBayer | Physical AppearancePowder and solvent that are made upto make solution. | Route of AdministartionSubcutaneous Injection | CategoryImmunosuppressive Agents, Antineoplastic, Antiviral, Immunologic factors | TargetInterferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
ID1343 | ThPPIDTh1049 | NameInterferon beta-1a | Peptide SequenceMSYNLLGFLQRSSNFQCQKL Full view | Length166 | Functional ClassificationIb | DiseaseCancer/Infectious/Immunological | BrandBetaseron | CompanyMerck | Physical AppearanceSterile, white to off-white powder | Route of AdministartionSubcutaneous Injection | CategoryImmunosuppressive Agents, Antineoplastic, Antiviral, Immunologic factors | TargetInterferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
ID1345 | ThPPIDTh1049 | NameInterferon beta-1a | Peptide SequenceMSYNLLGFLQRSSNFQCQKL Full view | Length166 | Functional ClassificationIb | DiseaseCancer/Infectious/Immunological | BrandExtavia | CompanyNovartis | Physical AppearanceSterile, white to off-white powder | Route of AdministartionSubcutaneous Injection | CategoryImmunosuppressive Agents, Antineoplastic, Antiviral, Immunologic factors | TargetInterferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
ID1368 | ThPPIDTh1054 | NameInfliximab | Peptide SequenceN.A. Full view | Length0 | Functional ClassificationIIa | DiseaseImmunological | BrandREMICADE | CompanyCentocor Inc | Physical AppearanceSterile, white, lyophilized powder, following reconstitution with 10 mL of Sterile Water for Injection, USP, the resulting pH is approximately 7.2. | Route of AdministartionIntravenous infusion | CategoryAntirheumatic Agents, Anti-Inflammatory Agents, Non-Steroidal, Dermatologic Agents, Gastrointestinal Agents and Immunosuppressive Agents | TargetTumor necrosis factor |
ID1376 | ThPPIDTh1057 | NameInterferon beta-1b | Peptide SequenceMSYNLLGFLQRSSNFQSQKL Full view | Length166 | Functional ClassificationIb | DiseaseImmunological | BrandBetaseron | CompanyBayer | Physical AppearanceSterile, white to off-white powder | Route of AdministartionSubcutaneous Injection | CategoryAdjuvants, Immunologic and Immunosuppressive Agents | TargetN.A. |
ID1377 | ThPPIDTh1057 | NameInterferon beta-1b | Peptide SequenceMSYNLLGFLQRSSNFQSQKL Full view | Length166 | Functional ClassificationIb | DiseaseImmunological | BrandBetaferon | CompanyBayer | Physical AppearancePowder and solvent that are made upto make solution. | Route of AdministartionSubcutaneous Injection | CategoryAdjuvants, Immunologic and Immunosuppressive Agents | TargetN.A. |
ID1378 | ThPPIDTh1057 | NameInterferon beta-1b | Peptide SequenceMSYNLLGFLQRSSNFQSQKL Full view | Length166 | Functional ClassificationIb | DiseaseImmunological | BrandExtavia | CompanyNovartis | Physical AppearanceSterile, white to off-white powder | Route of AdministartionSubcutaneous Injection | CategoryAdjuvants, Immunologic and Immunosuppressive Agents | TargetN.A. |
ID1385 | ThPPIDTh1061 | NameTrastuzumab | Peptide SequenceLight chain 1: DIQMT Full view | Length1364 | Functional ClassificationIIa | DiseaseCancer | BrandHerceptin | CompanyGenentech | Physical AppearanceSterile, white to pale yellow, preservative-free lyophilized powder | Route of Administartion Intravenous administration | CategoryAntineoplastic Agents | TargetInsulin receptor,Insulin-like growth factor 1 receptor,Insulin-degrading enzyme,HLA class II histocompatibility antigen, DQ alpha 2 chain,HLA class II histocompatibility antigen, DQ beta 1 chain,Retinoblastoma-associated protein,Cathepsin D,Carboxypeptidase E,Neuroendocrine convertase 2,Neuroendocrine convertase 1,Protein NOV homolog,Low-density lipoprotein receptor-related protein 2,Insulin-like growth factor-binding protein 7,Synaptotagmin-like protein 4 |
ID1403 | ThPPIDTh1065 | NameDigoxin Immune Fab (Ovine) | Peptide SequenceHeavy Chain: EVQLQQS Full view | Length438 | Functional ClassificationIIa | DiseaseCardiac | BrandDIGIBIND | CompanyGalaxo Smith Kline | Physical AppearanceSterile lyophilized powder of antigen binding fragments (Fab) derived from specific antidigoxin antibodies raised in sheep. | Route of AdministartionIntravenous infusion after reconstitution with Sterile Water for Injection | CategoryAntidotes | TargetT-cell surface glycoprotein CD3 delta chain, T-cell surface glycoprotein CD3 epsilon chain, T-cell surface glycoprotein CD3 gamma chain, T-cell surface glycoprotein CD3 zeta chain, Low affinity immunoglobulin gamma Fc region receptor III-B, Complement C1r subcomponent, Complement C1q subcomponent subunit A, Complement C1q subcomponent subunit B, Complement C1q subcomponent subunit C, Low affinity immunoglobulin gamma Fc region receptor III-A, Complement C1s subcomponent, High affinity immunoglobulin gamma Fc receptor I, Low affinity immunoglobulin gamma Fc region receptor II-a, Low affinity immunoglobulin gamma Fc region receptor II-b, Low affinity immunoglobulin gamma Fc region receptor II-c |
ID1415 | ThPPIDTh1069 | NamePegvisomant | Peptide SequenceFPTIPLSRLFDNAMLRAHRL Full view | Length191 | Functional ClassificationIIa | DiseaseHormonal | BrandSOMAVERT | CompanyPfizer | Physical AppearanceSterile, white lyophilized powder | Route of AdministartionSubcutaneous Injection | CategoryHormone Replacement Agents | TargetB-lymphocyte antigen CD20,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immunoglobulin gamma Fc region receptor III-A,High affinity immunoglobulin gamma Fc receptor I,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor II-c |
ID1421 | ThPPIDTh1070 | NameBotulinum Toxin Type A | Peptide SequenceMPFVNKQFNYKDPVNGVDIA Full view | Length1296 | Functional ClassificationIc | DiseaseNeurological Disorder | BrandXeomin | CompanyMERZ AESTHETICS | Physical AppearanceSterile white to off-white lyophilized powder after reconstitution with preservative-free 0.9% Saline for Injection. | Route of AdministartionIntramuscular Injection | CategoryNeuromuscular Blocking Agents, Anti-Wrinkle Agents and Antidystonic Agents | TargetGrowth hormone receptor |
ID1423 | ThPPIDTh1071 | NamePancrelipase | Peptide SequencePancreatic alpha amy Full view | Length1206 | Functional ClassificationIa | DiseaseMetabolic/genetic/ | BrandViokace | CompanyAptalis Pharma US, Inc. | Physical AppearanceBeige-white amorphous powder, miscible in water and practically insoluble in alcohol and converted to tablet form | Route of AdministartionOral route | CategoryGastrointestinal Agents and Enzyme Replacement Agents | TargetSynaptosomal-associated protein 25,Rho-related GTP-binding protein RhoB, Dietary fat,Dietary protein,Dietary starch |
ID1424 | ThPPIDTh1071 | NamePancrelipase | Peptide SequencePancreatic alpha amy Full view | Length1206 | Functional ClassificationIa | DiseaseMetabolic/genetic/ | BrandULTRESA | CompanyAptalis Pharma US, Inc. | Physical AppearanceBeige-white amorphous powder, miscible in water and practically insoluble or insoluble in alcohol and ether and converted to Delayed-Release Capsules | Route of AdministartionOral route | CategoryGastrointestinal Agents and Enzyme Replacement Agents | TargetSynaptosomal-associated protein 25,Rho-related GTP-binding protein RhoB, Dietary fat,Dietary protein,Dietary starch |